Regdanvimab（Cat No.:I042244）is a monoclonal antibody designed to target the spike protein of the SARS-CoV-2 virus, which causes COVID-19. By binding to the spike protein, Regdanvimab prevents the virus from entering human cells, thereby inhibiting infection. This antibody has been studied as a treatment for mild to moderate COVID-19 in patients who are at risk of progressing to severe disease. Regdanvimab has shown promise in reducing viral load and improving recovery times. It is typically administered intravenously and is part of ongoing efforts to develop effective treatments for COVID-19, particularly in high-risk populations.
